证券代码：002044 证券简称：美年健康 公告编号：2023-088 美年大健康产业控股股份有限公司 关于召开 2023 年第五次临时股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 美年大健康产业控股股份有限公司（以下简称"公司"）2023 年第五次临时股 东大会现场会议的召开地点为上海市静安区灵石路 697 号健康智谷 9 号楼三楼 公司会议室，敬请投资者特别留意。 根据公司于 2023 年 8 月 28 日召开的第八届董事会第二十七次会议，定于 2023 年 9 月 14 日召开公司 2023 年第五次临时股东大会，本次股东大会将采用 股东现场记名投票与网络投票表决相结合的方式召开，《关于召开 2023 年第五 次临时股东大会的通知》（公告编号：2023-085）已于 2023 年 8 月 30 日披露在 《中国证券报》、《上海证券报》、《证券时报》、《证券日报》和巨潮资讯网 （www.cninfo.com.cn）。现就本次股东大会的有关事宜发布提示性公告如下： 一、本次会议召开基本情况 1、股东大会届次：公司 2023 ...

证券代码:002044 证券简称:美年健康 美年大健康产业控股股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|-----------------------------------------|------------------------------------------|--------------------------------------| | | | | 编号:2023-05 | | 投资者关系活动类别 | □特定对象调研□业绩说明会 □□现场参观 | □分析师会议新闻发布会√其他(线上电话会议) | □媒体采访 □路演活动 | | | Allianz Global Investors Luxembourg S.A | 、 | AZInvestment 安中投资、Point72、Sage | | | Partners Limited、 | WT Asset Management Limited | 、景顺长城基金、富国基金、华 | | | | | | | | | | | | | | | | | | | | | ...

证券代码：002044 证券简称：美年健康 公告编号：2023-087 美年大健康产业控股股份有限公司 关于为下属子公司提供担保及反担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 美年大健康产业控股股份有限公司（以下简称"公司"或"美年健康"）于 2023 年 3 月 8 日召开的第八届董事会第二十二次（临时）会议及 2023 年 3 月 24 日召 开的公司 2023 年第二次临时股东大会，审议通过了《关于为下属子公司提供担保 及反担保额度的议案》。同意公司及下属子公司美年大健康产业（集团）有限公 司、东莞南城美年大健康门诊部有限公司及芜湖艾诺门诊部有限公司为下属子公 司向银行申请综合授信事项提供担保，本次新增担保额度累计不超过人民币 551,902 万元。同时公司为下属全资子公司成都锦江美年大健康维康体检门诊部有 限公司（以下简称"成都锦江美年"）的银行授信拟向成都中小企业融资担保有限责 任公司（以下简称"成都中小担保"）提供人民币 1,000 万元的连带责任反担保。具 体内容详见公司于 2023 年 3 月 9 日在巨潮 ...

证券代码:002044 证券简称:美年健康 美年大健康产业控股股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|--------------------------------------|------------------------------------------|-----------------------------| | | | | 编号:2023-04 | | 投资者关系活动类别 | □特定对象调研 □业绩说明会 □□现场参观 | √分析师会议新闻发布会√其他(线上电话会议) | 媒体采访路演活动 | | | | | | | 参与单位名称 | | | | | 及人员姓名 | | | | | | | | 24 家机构,以上排名不分先后) | | 时间 | 2023 年 8 月 30 | 日(周三)上午 9:30-11:00 | | | 地点 | 线上电话会议 | | | | 公司接待 | | | | | 人员姓名 | 秘书万晓晓女士 | | | | | | | 2023 年上半年运营情况 | 进行介绍 二、提问 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 4,405,411,317.91, representing a 49.87% increase compared to CNY 2,921,693,536.49 in the same period last year[11]. - The net profit attributable to shareholders of the listed company was CNY 10,144,667.02, a significant turnaround from a loss of CNY 666,482,473.37 in the previous year, marking a 101.52% improvement[11]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 3,391,307.96, compared to a loss of CNY 694,775,193.42 in the same period last year, reflecting a 100.49% increase[11]. - The net cash flow from operating activities was -CNY 111,475,804.87, an improvement of 69.30% from -CNY 365,149,309.28 in the previous year[11]. - Basic and diluted earnings per share were both CNY 0.0026, a recovery from -CNY 0.17 in the same period last year, indicating a 101.53% increase[11]. - The weighted average return on equity was 0.14%, a significant improvement from -8.66% in the previous year, representing an increase of 8.81 percentage points[11]. - The total assets at the end of the reporting period were CNY 17,957,610,838.86, a decrease of 1.76% from CNY 18,279,893,036.29 at the end of the previous year[11]. - The net assets attributable to shareholders of the listed company were CNY 7,470,190,398.03, showing a slight increase of 0.20% from CNY 7,455,349,420.97 at the end of the previous year[11]. Market Position and Strategy - The company is positioned as a leading player in the preventive medicine sector, focusing on high-quality health check services and expanding into areas such as artificial intelligence and tumor early screening[19]. - The company aims to meet the growing demand for personalized and high-quality health services, particularly in the wake of increased public health awareness post-COVID-19[18]. - The company is actively enhancing its service offerings by integrating value-added services and focusing on core areas such as health insurance and genetic testing[19]. - The company plans to continue expanding its market presence and enhancing service offerings in the health check sector[57]. - The company aims to expand its market presence through a multi-brand strategy, including "Meinian Health," "Ciming," "Aoya," and "Meizhao," catering to various customer segments[26]. Operational Efficiency and Quality Management - The company has implemented a comprehensive quality management system across all examination centers, enhancing operational efficiency and service quality[29]. - The company has established a standardized, specialized, and intelligent medical quality management system to enhance service quality and efficiency[72]. - The company has committed to improving health management capabilities and reducing national healthcare costs through its services[19]. - The company emphasizes a "medical-oriented, quality-driven" strategy, focusing on improving medical quality and customer satisfaction[28]. - The company has implemented a three-tier quality control system to ensure accountability and quality management across its health check facilities[46]. Research and Development - The company has allocated 100 million RMB for research and development in new health technologies, focusing on AI-driven health diagnostics[179]. - R&D investment for the period was ¥39,971,670.56, showing a slight increase of 2.38% from ¥39,041,324.18[50]. - The company is focusing on technological innovation, utilizing AI and big data to enhance the quality of health check services throughout the entire process[47]. Customer Engagement and Services - The average revenue per customer (ARPU) rose to 594 yuan, reflecting a 15% increase compared to the previous year[25]. - The company continues to innovate with new health examination products, including early screening for six major cancers, enhancing its service offerings[21]. - The company is leveraging digital health management platforms to upgrade its service offerings and improve customer engagement[20]. - The company has established a digital platform for personalized health management, improving service efficiency and reducing resource waste[88]. Community Engagement and Social Responsibility - The company provided free health check-ups to approximately 500 sanitation workers, each valued at over CNY 1,000[92]. - The company has been involved in various public welfare activities, including free health screenings for nearly 40,000 disabled individuals over the past seven years[90]. - The company organized a health care event for 60 self-employed "working mothers" to provide free health check-ups, enhancing awareness of personal health[93]. - The company launched a nationwide public health initiative focusing on women's health, mental health, lung health, and brain health, aiming to improve early screening and diagnosis awareness[93]. Financial Management and Investments - The company has not engaged in any securities or derivative investments during the reporting period[61]. - The company has committed to investing RMB 204.60 million in various projects, with a total of RMB 150.13 million invested as of the reporting date[64]. - The company reported a significant increase in accounts receivable, which reached approximately CNY 2.74 billion, accounting for 15.28% of total assets[54]. - The company has temporarily supplemented working capital with RMB 460 million of idle raised funds, with a usage period not exceeding 12 months[62]. Related Party Transactions - The company engaged in related party transactions, with a total amount of 6,259.68 million yuan for financing lease services, representing 0.74% of similar transactions[98]. - The total amount of related party transactions for 2023 is estimated to be no more than RMB 1,250.10 million, with actual transactions amounting to RMB 513.36 million by the end of the reporting period[103]. - The company reported a 12.52% increase in revenue from related party transactions with Beijing Meiyin Health Technology Co., Ltd., amounting to RMB 4,338.97 million[101]. Legal and Compliance - The company reported no significant litigation or arbitration matters during the reporting period, indicating a stable legal environment[96]. - The company has not faced any significant environmental pollution incidents during the reporting period and actively promotes green development[84]. - The semi-annual financial report has not been audited[137]. Future Outlook - The company provided a positive outlook for the second half of 2023, projecting a revenue growth of 25% driven by new product launches and market expansion strategies[179]. - The company plans to increase its marketing budget by 50% in 2024 to support brand awareness and customer acquisition initiatives[176].

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关于公司董事辞职的情况 美年大健康产业控股股份有限公司（以下简称"公司"）董事会于近日收到公 司董事吴瞳女士的书面辞职报告。因工作调整原因，吴瞳女士申请辞去公司第八 届董事会董事及董事会下属战略委员会委员、提名委员会委员职务。辞职后，吴 瞳女士不再担任公司任何职务。截至本公告披露日，吴瞳女士未持有公司股份。 根据《中华人民共和国公司法》、《公司章程》等相关规定，吴瞳女士的辞职 不会导致公司董事会成员低于法定最低人数，不会影响公司董事会的正常运作， 其辞职报告自送达公司董事会时生效。 公司及董事会对吴瞳女士在任职期间为公司发展作出的贡献表示衷心感谢！ 二、关于补选公司董事的情况 证券代码：002044 证券简称：美年健康 公告编号：2023-084 美年大健康产业控股股份有限公司 关于董事辞职及补选董事的公告 美年大健康产业控股股份有限公司 董 事 会 二〇二三年八月三十日 公司于 2023 年 8 月 28 日召开了第八届董事会第二十七次会议，审议通过了 《关于补选公司第八届董事会非独立董事的议案》，根据公司 ...

证券代码：002044 证券简称：美年健康 公告编号：2023-082 美年大健康产业控股股份有限公司 关于公司下属子公司开展售后回租融资租赁业务 暨公司提供担保的公告 单位：万元 | 序号 | 债权人 | 拟承租人 | 融资 | 融资期限 | 融资 | 保证金 | 服务 | 还款 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 东莞南城慈铭诊所 | 额度 | （年） | 利率 | | 费 | 方式 | | | | 有限公司、长沙美年 大健康健康管理有 | | | | | | | | | 前海兴 | 限公司、临沂慈铭健 | | | | | | | | | 邦金融 | 康体检管理有限公 | | | | | | 等额 | | 1 | 租赁有 | | 10,000 | 3 | 5.88% | 500 | 0 | | | | | 司、郑州美年大健康 | | | | | | 季付 | | | 限责任 | | | | | | | | | | 公司 | 科技有限公司、福清 | | | | | | | | | | 市美年大健康管理 | | | | ...

美年大健康产业控股股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：美年大健康产业控股股份有限公司 单位：万元 | | 资金占用 | 占用方与上 | 上市公司核 | 2023 年期 | 2023 年半年度 | 2023 年半年度 | 2023 年半 | 2023 年 | 6 占用形 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 方名称 | 市公司的关 | 算的会计科 | 初占用资 | 占用累计发生金 | 占用资金的利 | 年度偿还累 | 月末占用 | 成原因 | 占用性质 | | | | 联关系 | 目 | 金余额 | 额（不含利息） | 息（如有） | 计发生金额 | 资金余额 | | | | 控股股东、实际控制 | | | | | | | | | | 非经营性占用 | | 人及其附属企业 | | | | | | | | | | | | 小计 | - | - | - | | | | | | | - | | 前控股股东、实际控 | | | | | | ...

证券代码：002044 证券简称：美年健康 公告编号：2023-083 美年大健康产业控股股份有限公司 关于签署投资顾问合同终止协议暨关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、关联交易概述 1、美年大健康产业控股股份有限公司（以下简称"公司"）于 2017 年 4 月 25 日召开第六届董事会第二十八次（临时）会议，审议通过了《关于公司参与 投资产业并购基金暨关联交易的议案》，同意公司参与投资上海健亿投资中心（有 限合伙）（以下简称"上海健亿"），并与上海天亿资产管理有限公司（以下简称"天 亿资产"）等公司签署《关于上海健亿投资中心（有限合伙）之合伙协议》（以下 简称"合伙协议"），合伙协议约定公司将作为上海健亿的投资顾问，为其投资业 务提供顾问咨询服务。具体内容详见公司于 2017 年 4 月 26 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于公司参与投资产业并购基金暨关联交易的公 告》（公告编号：2017-031）。 公司于 2017 年 6 月 23 日召开第六届董事会第三十一次（临时）会议，审议 通过了《 ...

证券代码：002044 证券简称：美年健康 公告编号：2023-081 美年大健康产业控股股份有限公司 关于为下属子公司提供担保及反担保额度的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 本次被担保对象中金华市美年大健康医疗管理有限公司（以下简称"金华美 年"）等 7 家下属子公司的资产负债率超过 70%，请投资者充分关注担保风险。 本次担保尚需提交公司股东大会审议。 一、情况概述 （一）担保基本情况 因经营发展需要，美年大健康产业控股股份有限公司（以下简称"美年健康"、 "公司"、"本公司"）及公司下属全资子公司长沙美年大健康健康管理有限公司（以 下简称"长沙美年"）拟为下属子公司向银行申请综合授信事项提供担保，本次拟新 增担保额度累计不超过人民币 8,300 万元，占公司最近一期经审计归属于母公司 净资产的 1.11%。其中，为资产负债率 70%以上的子公司担保不超过 7,300 万元， 占公司最近一期经审计归属于母公司净资产的 0.98%，为资产负债率 70%以下的 子公司担保不超过 1,000 万元，占公司最近一期经审计归属于母公司 ...